Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23642757 | 1.00 | ALDH1A1 (0.38) | ALDH1A1KMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL12918820 | 0.92 | HDAC3 (0.47) | KMT2AMEN1SMN1; SMN2HPGDHTT | |
| SCHEMBL2625073 | 0.92 | TP53 (0.41) | KMT2AMEN1POLBSMN1; SMN2HPGD | |
| SCHEMBL19703758 | 0.92 | SMN1; SMN2 (0.43) | ALDH1A1KMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL19703757 | 0.91 | SMN1; SMN2 (0.48) | ALDH1A1KMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL19703805 | 0.91 | CASP2 (0.46) | ALDH1A1KMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL19704167 | 0.89 | SMN1; SMN2 (0.50) | ALDH1A1KMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL18712561 | 0.89 | SMN1; SMN2 (0.50) | ALDH1A1KMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL24848307 | 0.89 | CASP2 (0.49) | ALDH1A1KMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL19703885 | 0.89 | SMN1; SMN2 (0.38) | ALDH1A1KMT2AMEN1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087853-B1 | NEW IMMUNOSTIMULATORS AND USE THEREOF IN IMMUNOTHERAPY | UNIV NANTES (FR) | 2023-10-18 | — | — | EP | disclosed |
| US-20230303649-A1 | MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-09-28 | — | — | US | disclosed |
| WO-2021140203-A1 | NEW IMMUNOSTIMULATORS AND USE THEREOF IN IMMUNOTHERAPY | UNIVERSITE DE NANTES (FR) | 2021-07-15 | — | — | WO | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-9745359-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | ADDA BIOTECH INC. (CN) | 2017-08-29 | — | — | US | disclosed |
| US-20170233447-A1 | PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF | ADDA BIOTECH INC. (CN) | 2017-08-17 | — | — | US | disclosed |
| US-9579367-B2 | C-terminally tethered amino acids and their fibrinolytic therapeutic uses | CANADIAN BLOOD SERVICES (CA) | 2017-02-28 | — | — | US | disclosed |
| EP-2813567-B1 | C-terminally tethered amino acids and their fibrinolytic therapeutic uses | CANADIAN BLOOD SERVICES (CA) | 2017-02-08 | — | — | EP | disclosed |
| WO-2016118932-A1 | BRANCHED AND LINEAR CHIMERIC COMPOUNDS, POLYNUCLEOTIDES, USES AND METHODS FOR PREPARATION THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20160213774-A1 | BRANCHED AND LINEAR CHIMERIC COMPOUNDS, POLYNUCLEOTIDES, USES AND METHODS FOR PREPARATION THEREOF | DYNAVAX TECHNOLOGIES CORPORATION | 2016-07-28 | — | — | US | disclosed |
| US-20150183847-A1 | PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF | ADDA BIOTECH INC. (CN) | 2015-07-02 | — | — | US | disclosed |
| US-20140369992-A1 | C-Terminally Tethered Amino Acids and Their Fibrinolytic Therapeutic Uses | CANADIAN BLOOD SERVICES (CA) | 2014-12-18 | — | — | US | disclosed |
| US-7846896-B2 | PEG conjugates of NK4 | HOFFMAN-LA ROCHE INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7459429-B2 | Method of treating disturbances of iron distribution in inflammatory intestinal diseases | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459435-B2 | Treatment of disturbances of iron distribution | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459436-B2 | Treatment of disturbances of iron distribution | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080085857-A1 | conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 | BRANDT MICHAEL | 2008-04-10 | — | — | US | disclosed |
| US-7202208-B2 | Erythropoietin composition | HOFFMAN-LA ROCHE INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7169754-B2 | Erythropoietin composition | HOFFMANN-LA ROCHE INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213774-A1 | BRANCHED AND LINEAR CHIMERIC COMPOUNDS, POLYNUCLEOTIDES, USES AND METHODS FOR PREPARATION THEREOF | PAICS, PBK, PHAX | ALDH1A1 4448/4885KMT2A 2816/4885MEN1 3016/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | ALDH1A1 3212/4885KMT2A 2505/4885MEN1 1913/4885 |
| US-20230303649-A1 | MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | IL2, IL2RA, ICOS | ALDH1A1 4215/4885KMT2A 1964/4885MEN1 4197/4885 |
| US-20140369992-A1 | C-Terminally Tethered Amino Acids and Their Fibrinolytic Therapeutic Uses | HABP2, FGB, PROC | ALDH1A1 4658/4885KMT2A 2918/4885MEN1 2644/4885 |
| US-20080085857-A1 | conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 | PBK, IL4, CD47 | ALDH1A1 2899/4885KMT2A 305/4885MEN1 2418/4885 |
| US-20150183847-A1 | PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF | GLP1R, GIPR, IAPP | ALDH1A1 3100/4885KMT2A 3698/4885MEN1 852/4885 |
| US-20170233447-A1 | PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF | GLP1R, GIPR, IAPP | ALDH1A1 3111/4885KMT2A 3645/4885MEN1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.